Sayda M. Elbashir

This study develops and evaluates two mRNA vaccines targeting the LP.8.1 variant of SARS-CoV-2, showing broad neutralization against JN.1-lineage subvariants.

This study evaluates JN.1 and KP.2 mRNA vaccines in mice, showing they elicit strong neutralizing antibodies against JN.1 subvariants and cross-neutralize KP.3, LA.2, and XEC.

This study shows that boosting mice with mRNA vaccines in the ipsilateral or contralateral arm leads to equivalent immune responses and protection against SARS-CoV-2 Omicron.

This study shows that intestinal helminth infection reduces T cell responses to an mRNA SARS-CoV-2 vaccine and weakens protection against Omicron but not the ancestral strain.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.